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Epstein–Barr virus (EBV)-associated posttransplant
lymphoproliferative disorder (PTLD) remains a major
cause of morbidity and mortality after hematopoietic
stem cell (HSCT) or solid organ transplant (SOT).
Strategies to reconstitute immunity by adoptive
transfer of EBV-specific cytotoxic T lymphocyte (CTL)
therapy while highly effective in the HSCT setting
where immunosuppression can be withdrawn have
been less successful in the SOT setting where contin-
ued immunosuppression therapy is necessary. Addi-
tionally, the complexity and time taken to generate
EBV-CTLs for adoptive transfer limit the clinical
applicability. We have developed a system for the
rapid generation of EBV-CTLs resistant to immuno-
suppression based on selection of interferon-gamma
(IFN-g) secreting EBV-CTLs and retroviral transduction
with a calcineurin B mutant. With this methodology,
EBV-CTLs resistant to the calcineurin inhibitor Tacro-
limus (TAC) can be produced in 14 days. These CTLs
show high specificity for EBV with negligible allor-
eactivity in both proliferation and cytotoxicity assays
and are able to proliferate and secrete IFN-g in
response to antigen stimulation in the presence of
therapeutic doses of TAC. This strategy will substan-
tially facilitate clinical application of this approach for
the treatment of PTLD in SOT recipients.
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Introduction
Epstein–Barr virus (EBV)-associated posttransplant lym-
phoproliferative disorder (PTLD) is a major complication of
solid organ (SOT) or hematopoietic stem cell transplant
(HSCT) arising because immunosuppression compromises
virus-specific CTL immunosurveillance, allowing uncon-
trolled proliferation of EBV-infected B cells (1,2). Current
therapies for PTLD are frequently ineffective and have
significant toxicity. Reducing immunosuppression fre-
quently results in graft rejection: indeed in one large series,
death from graft rejection was as frequent as death from
PTLD (3–6). Adoptive immunotherapy represents a logical
approach to reconstitute EBV-CTL-mediated immunity and
has been shown to be highly effective in the HSCT
setting (3,4,7). In contrast, the application of this strategy
for the treatment of PTLD in SOT patients, while
feasible (5,6,8), is compromised by the ongoing immuno-
suppression required to prevent graft rejection (9,10).
Our group has developed (11) a strategy for genetically
engineering EBV-CTLs to be resistant to calcineurin
inhibitors, the most critical immunosuppressive drugs
used after SOT. Cyclosporin A (CsA) and Tacrolimus
(TAC) function by binding to cyclophilin (CyPA) and FK
binding protein-12 (FKBP-12), respectively. These com-
plexes inhibit the calcium-sensitive phosphatase calci-
neurin from binding to the transcription factor nuclear
factor of activated T cells (NFAT), preventing T cells
activation. To neutralize the immunosuppressive effects
of these drugs, we have developed calcineurin mutants
disrupting binding of TAC–FKBP-12 and/or CsA–CyPA,
without affecting the active site responsible for NFAT
dephosphorylation. EBV-CTLs expressing such mutants
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maintain their ability to proliferate and secrete interferon-
gamma (IFN-g) in response to stimulation with EBV in the
presence of therapeutic levels of TAC and/or CsA (11).
The conventional methodology used to generate EBV-CTLs
involves stimulation with autologous EBV-transformed B
cells (lymphoblastoid cell line [LCL) (12,13). This utilizes a
live virus (B95-8) and takes at least 12weeks limiting clinical
applicability as during this time, themajority of patientswith
PTLD would have either succumbed or responded to
alternative therapies. A simpler, more rapid system for the
isolation of EBV-CTLs is therefore needed. Several groups
have used the cytokine capture assay (14,15) based on
selection of IFN-g after antigenic stimulation to rapidly
isolate virus-specific T cells. Recently, two groups (16,17)
have isolated EBV-CTLs from normal donor blood
after stimulation with pools of immunodominant EBV
peptide epitopes. This approach was successfully used
clinically with donor derived EBV-CTLs in HSCT recipients.
We hypothesized that combination of this methodology
with genetic modification of the isolated EBV-CTLs
to render them resistant to calcineurin inhibitor would
enable us to extend adoptive immunotherapy to the SOT
setting.
Here we describe a simple, rapid and robust methodology
for the generation of EBV-CTLs resistant to calcineurin
inhibitors using IFN-g capture after peptide stimulation,
followed by retroviral transduction with the CNb30 mutant.
This strategy may increase the efficacy of adoptively
transferred EBV-CTLs in SOT patients developing PTLD and
avoid the need for withdrawal of immunosuppression.
Materials and Methods
EBV peptides
The EBV peptide mix used (JPT Peptide Technologies, Berlin, Germany)
consists of 23 immunodominant peptides (19 HLA class I restricted and 4
HLA class II) from 5 latent antigens (LMP2, EBNA1, EBNA3A, EBNA3B,
EBNA3C), 4 immediate early/early antigens (BZLF1, BRLF1, BMLF1,
BHRF1) and 2 late/structural antigens (BLLF1, BNRF1) as previously
described (16).
Generation of EBV-specific T-lymphocyte lines
A total of 2–5 108 peripheral blood mononuclear cells (PBMCs) were
stimulated with EBV pepmix at 1mg/mL in X-Vivo15þ 2% human AB Serum
(Lonza, Slough, UK) as previously reported (16). After a 16-h stimulation
period, IFN-g-secreting cells were selected using the IFN-g secretion assay
according to the manufacturer’s recommendations (Miltenyi Biotec, Bisley,
UK). Briefly, PBMCs were labeled with a bi-specific anti-IFN-g/CD45
antibody, and incubated for 45min at 378C to enable IFN-g secretion. Cells
that bound IFN-gwere labeled with magnetic beads conjugated with an IFN-
g-specific antibody, and IFN-g positive secreting cells were selected using
Miltenyi Mini-MACS columns.
EBV-CTLs were expanded in culture for 2 weeks. Selected EBV-specific T
cells were resuspended at 3 105 cells/mL in plus 100U/mL IL-2 (Proleukin;
Chiron, Ratingen, Germany) in the presence of 5 106/mL autologous,
irradiated (30Gy) PBMCs. After 7 days, T cells were re-plated at 5 105 T
cells/well with autologous pepmix pulsed, irradiated PBMCs at a ratio of 1:8.
Generation of retrovirus
High-titer stable SFG retroviral producer lines carrying either the enhanced
green fluorescent protein (eGFP) transgene alone or expressed with the
CNb30 mutant pseudotyped with Gibbon Ape Leukemia Virus envelope (18)
were produced as described previously (11). The titers of the retroviral
vectors were, respectively, for CNb30 4.8 106 cells/mL, and for eGFP
9.3 106 cells/mL.
Transduction of EBV-CTLs
EBV-CTLs were transduced with CNb30 mutants or eGFP retroviral
supernatants 3 days after the second peptide stimulation as previously
described (11). Transduction efficiency was determined by expression of
eGFP by flow cytometry.
For methodology for donors, immunophenotyping, tetramer staining,
generation of LCLs, cytotoxicity assays, proliferation, enzyme-linked
immunosorbent assay (ELISA) and statistical analysis, see Supplementary
Material Online.
Results
Generation, expansion and transduction of EBV-CTLs
Amean of 3.5 106 EBV-CTLs (range 0.3106 to 6.2 106
(n¼5) was obtained after selection of the IFN-g secreting T
cells. To obtain a suitable yield for clinical application, we
expanded the isolated EBV-CTLs with autologous peptide
loaded PBMCs as feeders. To render EBV–CTLs resistant
to calcineurin inhibitors, cells were transduced on day 10
with retroviral vectors carrying eGFP transgene alone or
expressed with the calcineurin mutant CNb30 (11). After
14 days of culture, the mean number of cells obtained was
46.9 106 (range 30–70 106) (Figure 1). Transduction
efficiency assessed at day 14 was between 18% and
80.6% (CNb30 mean 37%, range 18–72%; eGFP mean
64.5%, range 46.3–80.6%). Thus, with this methodology
we could achieve a 13.4-fold of the EBV-CTLs over 14 days.
EBV-CTLs are mainly CD8þ with an effector memory
phenotype
We next evaluated the immunophenotype of EBV-CTLs,
and consistent with the fact that the EBV pepmix used to
generate the EBV-CTLs contain mainly CD8 epitopes, flow
cytometric analysis showed that the majority (mean 70%,
range 4.1–97.7%) of the EBV-CTLs were CD8þ but a
significant proportion (mean 30%, range 2.3–95%), were
CD4þ; 1.4% of the cells showed a natural killer (NK)
phenotype (CD3CD56þCD16þ) and 2.2% were natural
killer T cells (CD3þCD56þCD16þ) (Figure 2A). The majority
of the T cells in all five donors showed a CCR7 CD45RA
effector memory phenotype (mean 93.6%, range 76.3–
99.6%) (Figure 2B), hence consisting mainly of T cells with
the capacity for immediate effector function and durable
memory responses. Comparison of the phenotype of
untransduced and CNb30 transduced EBV-CTLs showed
Rapid Generation of EBV-CTLs Resistant to Immunosuppression
3245American Journal of Transplantation 2013; 13: 3244–3252
that transduction with calcineurin mutant did not alter the
phenotype of EBV-CTLs (Figure 2B).
Enrichment of EBV antigen specificity
To demonstrate that our protocol enriched for EBV-CTLs, in
three donors with the appropriate HLA restriction, we
compared the frequency of CD8þT cells specific for EBV
using HLA-peptide tetramers in unmanipulated PBMCs and
in selected, expanded, transduced CTLs from the same
donor (Table 1). All three donors showed enrichment of
EBV-tetramer-positive T cells in transducedCTLs compared
with the starting PBMCs. In donor 2we observed a fourfold
increase of CD8þ T cells recognizing BZLF1 (RAK) in CTLs
compared with PBMCs, in donor 3 a threefold increase for
EBNA3A (RLR)-specific CD8þ T cells and in donor 5
eightfold increase for BMLF1 (GLC), twofold for LMP2
(CLG) and sixfold for BZLF1 (RAK)-specific CD8þ T cells
(Figure 2C).
EBV-CTLs kill EBV-infected targets
In order to determine whether EBV-CTLs were able to lyse
EBV-infected targets we performed 51Cr release cytotoxic-
ity assays. Both CNb30 and eGFP CTLs showed specific
Figure 2: Phenotype and antigen specificity of EBV-CTLs. Flow
cytometric immunophenotyping was performed on day 14 after
expansion. (A) Untransduced and CNb30 transduced EBV-
CTLs were analyzed for T and NK-cell marker expression. (B)
Distribution of memory subsets in untransduced (UT) and CNb30
transduced EBV-CTLs. Effector memory (CCR7 CD45RA), na€ıve
(CCR7þCD45RAþ), central memory (CCR7þCD45RA), terminal-
differentiated (TD) effector (CCR7-CD45RAþ) T cells. Cells were
gated on CD3þ cells. Mean expressionSEM in EBV T cell lines
generated from five donors are shown. (C) Enhancement of EBV
specificity in CD8þ cells from one donor with appropriate HLA
restriction. Flow cytometry profile of EBV-CTLs stained with
anti-CD8 mAb and with relevant HLA class I/peptide tetramer. The
left plot shows the frequency of tetramer-positive cells on
peripheral blood mononuclear cells before the isolation and
expansion. Right plot shows that isolated, expanded EBV-CTLs
transduced with CNb30 mutant have an increased frequency of
tetramer-positive T cells. CTL, cytotoxic T lymphocyte; EBV,
Epstein–Barr virus.
Figure 1: Growth kinetics of EBV-CTLs generated with IFN-g
capture. The graph illustrates the expansion rate of EBV-CTL lines
after selection with IFN-g capture. PBMCs from five EBV
seropositive donors were stimulated with EBV pepmix. IFN-g
secreting T cells were selected and expanded with autologous,
irradiated PBMCs as feeder cells. On day 7 after initial stimulation
CTLs were restimulated using pepmix-pulsed autologous PBMCs.
Onday10EBV-CTLswere transducedwith retroviral vectors carrying
a control vector containing the enhanced green fluorescent protein
transgene alone or expressed with the calcineurin mutant CNb30.
The figure shows theexpansionof CTLs fromthebeginning (day0) to
day 14, following a second stimulation at day 7 and transduction at
day 10. CTLs expansion was evaluated using Trypan blue exclusion
and results are shown as mean cell numberSD. The total cell
number of T cells obtained was 13.4-fold expanded over 14 days.
CTL, cytotoxic T lymphocyte; EBV, Epstein–Barr virus; IFN-g,
interferon-gamma; PBMCs, peripheral blood mononuclear cells.
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cytotoxicity against autologous LCL targets (Figure 3A and
B). CNb30-CTLs showed a mean lysis of 24.45%SE
4.5% (at an effector:target ratio of 30:1, n¼4) and GFP-
CTLs a mean lysis of 20.23%SE 2.6 (at a 30:1 effector:
target ratio, n¼ 4). This lysis wasMHC restricted as no lysis
of allogeneic LCLs was observed (mean 1.8%SE 0.3%)
and not NK-mediated as no significant cytotoxicity against
theHSB2 cell line (mean 3.48%, range 3–6.5%at 30:1 ratio)
was seen. To determine whether immunosuppression
could have an effect on the cytotoxic ability of the EBV-
CTLs, we cultured the CTLs in presence of therapeutic
levels (10 ng/mL) of TAC before and during the cytotoxicity
assay. We did not observe any difference in the cytotoxic
activity against autologous LCLs for either CNb30 or eGFP-
CTLs treated with TAC (CNb30 36.84%, eGFP 24.65% at
30:1 effector:target ratio; Figure 3C and D). These data
demonstrate that the cytotoxicity of EBV-CTL lines is not
affected by retroviral transduction with CNb30 and that the
presence of calcineurin inhibitors has no effect on the
cytotoxicity of EBV-CTL lines.
Table 1: Specificity of EBV-CTLs after selection and expansion analyzed by tetramer staining
Donor HLA type Tetramer EBV antigen PBMCs (%) CNb30 CTLs (%)
D2 A01,31; B08,60 HLA-B0801-RAKFKQLL BZLF1 3.32 16
D3 A03,29; B39 HLA-A0301-RLRAEAQVK EBNA3A 5.07 16.1
D5 A01,02; B08 HLA-A0201-GLCTLVAML BMLF1 1.11 9.92
HLA-A0201-CLGGLLTMV LMP2 2.5 4.8
HLA-B0801-RAKFKQLL BZLF1 5.51 32.7
After interferon-gamma selection and 14 days in vitro expansion, the EBV-specificity of the selected, expanded and CNb30 transduced cells
was analyzed using tetramer staining. The frequency of T cells specific for an HLA-EBV peptide epitope was determined by staining T cells
with CD3 APCCy7, CD8 Pacific Blue and Tetramer. Table shows the frequency of tetramer-specific T cells in the starting unmanipulated
fraction (PBMCs) and in the selected, expanded and CNb30 transduced CTL (CNb30 CTL) populations in three donors with the appropriate
HLA restrictions. The percentages refer to the proportion of the CD8þ cells positive for the corresponding tetramer with the isotype control
subtracted. CTL, cytotoxic T lymphocyte; EBV, Epstein–Barr virus; PBMCs, peripheral blood mononuclear cells.
Figure 3: Cytotoxic activity of EBV-CTLs. A standard 51Cr release cytotoxicity assay was performed to assess cytotoxicity of EBV-CTL
lines against autologous, mismatched LCL targets or the T cell line HSB2. (A) Cytolytic activity of CNb30 transduced cells; (B) cytolytic
activity of EBV-CTLs transducedwith eGFP alone. Cytotoxic ability of EBV-CTLs transducedwith CNb30 (C) or with eGFP alone (D) cultured
in the presence of 10 ng/mL of Tacrolimus. No effect of calcineurin inhibitors was detected on cytotoxicity of either eGFP or CNb30
transduced EBV-CTLs. Both EBV-CTLs transduced with CNb30 or with eGFP alone show higher cytotoxic ability against autologous LCLs
compared with mismatched targets or the HSB2 cell line. The mean valuesSEM in four donors tested are shown. CTL, cytotoxic T
lymphocyte; EBV, Epstein–Barr virus; eGFP, enhanced green fluorescent protein; LCLs, lymphoblastoid cell lines.
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EBV-CTLs transduced with calcineurin mutant
secrete IFN-g, proliferate in the presence of TAC and
lack alloreactivity
To assess the ability of CNb30-CTLs to function in the
presence of TAC, we measured IFN-g release and
proliferation in response to antigenic stimulation. As shown
in Figure 4A and B, addition of TAC to eGFP-CTLs
completely inhibited secretion of IFN-g (p< 0.05, n¼5)
and abrogated proliferation (p<0.05) after stimulation with
EBV pepmix. In contrast, all five CNb30-CTLs were able to
secrete IFN-g (p¼0.42) and proliferate (p¼ 0.4) in presence
of TAC at comparable levels to CNb30-CTLs in the absence
of TAC. Neither CNb30 nor eGFP CTLs secreted IFN-g or
showed any proliferation when cultured with AdV5, a
control irrelevant peptide, demonstrating the antigen
specificity of our CTL lines. These data demonstrate that
CNb30-CTLs are able to secrete effector cytokines and to
proliferate in response to antigen stimulation in the
presence of TAC.
If TAC resistant CTLs are to be used in the allogeneic
setting, it is critical that they are depleted of alloreactivity by
the process of selection and culture. We therefore
measured the alloreactivity of the eGFP/CNb30-CTLs in a
mixed lymphocyte reaction, and compared this with the
alloreactivity of unmanipulated PBMCs from the same
donor. Donor PBMCs or selected EBV-CTLs were cultured
with irradiated, HLA mismatched PBMCs for 6 days. As
shown in Figure 4C, unmanipulated donor PBMCs prolifer-
ated strongly in response to stimulation with irradiated,
allogeneic PBMCs (p¼ 0.0001). In contrast, the response of
CNb30-CTLs to allogeneic PBMCs was negligible. The
absence of proliferation in response to allogeneic PBMCs
indicates that the process of IFN-g selection, expansion and
transduction of EBV-CTLs diminish their alloreactivity.
Generation of TAC resistant EBV-CTLs from SOT
patients receiving immunosuppression
To ensure that the approach we describe would be feasible
using T cells from SOT patients with PTLD, we isolated
EBV-CTLs using our methodology above from three SOT
patients (two heart transplants, one small bowel transplant)
with PTLD and transduced them with the CNb30. All three
patients were receiving TAC.
Figure 4:
———————————————————
Figure 4: EBV-CTLs transduced with CNb30 secrete IFN-g
retain proliferative ability in the presence of TAC and lack of
alloreactivity. Selected, expanded and transduced EBV-CTLs
were stimulated in the presence of EBV pepmix with or without
TAC and IFN-g secretion was assessed by ELISA 24h after
stimulation. (A) EBV-CTLs transduced with CNb30 were able to
secrete IFN-g in the presence of EBV pepmix plus 10 ng/mL TAC at
comparable levels to that seen with CNb30 transduced T cells
stimulated with EBV pepmix alone (p¼0.42). eGFP transduced
EBV-CTLs did not produce IFN-g in the presence of EBV pepmix
plus 10ng/mL TAC compared with eGFP transduced T cells
stimulated with EBV pepmix alone (p<0.05). Results also show
that both CNb30 and GFP transduced EBV T cells do not produce
IFN-g when stimulated with an irrelevant peptide (Adeno hexon).
Proliferation ability of EBV-CTLs was evaluated 4 days after
stimulation with EBV pepmix with or without TAC and was tested
by H3-thymidine uptake for 21 h. (B) Proliferation of eGFP
transduced EBV-CTLs after stimulation with EBV pepmix in the
presence of TAC was significantly inhibited (p<0.05) compared
with CNb30 transduced EBV-CTLs (p¼0.4). These data also show
that both CNb30 and GFP transduced EBV-CTLs do not proliferate
in the presence of an irrelevant peptide (Adeno hexon). (C)
Alloreactive potential of unmanipulated PBMCs as well as
selected, expanded and transduced EBV-CTLs from the same
donor using a primary mixed lymphocyte reaction. Unmanipulated
unselected PBMCs proliferated significantly (p<0.0005) in
response to allogeneic, irradiated PBMCs compared to the
proliferation of the selected EBV-CTLs. Data show the mean
values and SEM of experiments from five donors. CTL, cytotoxic T
lymphocyte; EBV, Epstein–Barr virus; eGFP, enhanced green
fluorescent protein; IFN-g, interferon-gamma; PBMCs, peripheral
blood mononuclear cells; TAC, Tacrolimus.
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As these patients were children, we started with 30–60mL
of blood. EBV-CTLs were generated by stimulating PBMCs
with the pepmix for 16 h followed by IFN-g capture assay. A
mean of 0.14 106 EBV-CTLs (range 0.08 106 to
0.18106) was obtained after selection. The isolated
EBV-CTLs were expanded and transduced using the
method above. After 14 days of culture, the mean number
of cells obtained from three patients was 8.92 106 (range
3.16–17.8 106) (Figure 5A). Transduction efficiency as-
sessed at day 14 was between 56.7% and 84.2% (CNb30
mean 62.35%, range 56.7–68%; eGFP mean 83.25%,
range 82.3–84.2%). Thus, we could achieve a 63.5-fold
expansion of the EBV-CTLs over 14 days even in PTLD
patients.
The majority of the EBV-CTLs generated from these
patients were CD8þ (data not shown). Comparison of the
frequency of CD8þT cells specific for the immunodominant
EBVepitopeRAKFKQLL fromBZLF1 in one evaluable donor
showed a marked (17.7-fold) enrichment of tetramer-
positive cells in selected, expanded, transduced CTLs
compared with unmanipulated PBMCs from the same
donor (Figure 5B).
To assess the ability of CNb30-CTLs from PTLD patients to
function in the presence of TAC; we measured IFN-g
release and proliferative ability in response to antigenic
stimulation. Our data show (Figure 5C and D) that addition
of TAC to eGFP-CTLs completely inhibited secretion of IFN-
g (p< 0.05, n¼ 3) and abrogated proliferation (p< 0.05)
after stimulation with EBV pepmix. In contrast, CNb30-
CTLs were able to secrete IFN-g (p¼ 0.0884, n¼ 3) and to
proliferate (p¼ 0.18) in presence of TAC at comparable
levels to CNb30-CTLs its absence. Neither CNb30 nor eGFP
Figure 5: Expansion, antigen specificity and function in vitro of EBV-CTLs from SOT patients with PTLD. The growth kinetics, and
antigen specificity by tetramer staining of the EBV-CTLs isolatedwith IFN-g capture, expanded in vitro and transducedwith CNb30 from our
cohort of SOT recipients are shown. (A) Expansion of CTLs from the beginning (day 0) to day 14, following a second stimulation at day 7 and
transduction at day 10. CTLs expansion was evaluated using Trypan blue exclusion and results are shown as mean cell numberSD. The
total cell number of expanded T cells obtainedwas 63.5-fold over 14 days. (B) Enhancement of EBV specificity in CD8þ cells from one PTLD
patient with appropriate HLA restriction. Flow cytometry profile of EBV-CTLs stained with anti-CD8 mAb and with relevant HLA class I/
peptide tetramer. The left plot shows the frequency of tetramer-positive cells on PBMCs before the isolation and expansion. Right plot
shows that isolated, expanded EBV-CTLs transduced with CNb30 mutant have an increased frequency of tetramer-positive T cells.
Selected, expanded and transducedEBV-CTLswere stimulated in the presence of EBVpepmixwith orwithout TACand IFN-g secretionwas
assessed by ELISA 24h after stimulation. (C) EBV-CTLs transducedwith CNb30 were able to secrete IFN-g in the presence of EBV pepmix
plus 10 ng/mL TAC at comparable levels to that seen with CNb30 transduced T cells stimulated with EBV pep mix alone (p¼0.08). eGFP
transduced EBV-CTLs did not produce IFN-g in the presence of EBV pepmix plus 10 ng/mL TAC compared with eGFP transduced T cells
stimulatedwith EBV pepmix alone (p<0.05). (D) Proliferationwas tested by H3-thymidine uptake for 21h after 4 days of stimulationwith
EBV pepmixwith orwithout TAC. Proliferation of eGFP transducedEBV-CTLs after stimulationwith EBV pepmix in the presence of TACwas
significantly inhibited (p<0.05) compared with CNb30 transduced EBV-CTLs (p¼0.18). These data also show that both CNb30 and GFP
transduced EBV-CTLs from PTLD patients do not secrete IFN-g or proliferate when stimulated with an irrelevant peptide (Adeno hexon).
Data show themean values and SEM of experiments from three patients examined. CTL, cytotoxic T lymphocyte; EBV, Epstein–Barr virus;
eGFP, enhanced green fluorescent protein; IFN-g, interferon-gamma; PBMCs, peripheral blood mononuclear cells; PTLD, posttransplant
lymphoproliferative disorder; SOT, solid organ transplant; TAC, Tacrolimus.
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CTLs secreted IFN-g or showed proliferationwhen cultured
with a control irrelevant peptide, demonstrating the antigen
specificity. Taken together these results show that CNb30-
CTLs isolated from PTLD patients have an effective
immunological response to EBV that is not abrogated in
the presence of TAC.
Discussion
Adoptive transfer of ex vivo derived EBV-CTLs prevents or
ameliorates PTLD by reconstituting the EBV-specific T cell
immunity after HSCT (4,19) but in the SOT setting has been
more challenging (5,6,20,21). First, CTL generation requires
the use of live, replication-competent EBV virus (B95-8) for
LCL generation and is time-consuming (12). Second, SOT
patients require ongoing immunosuppression to prevent
rejection and this limits the proliferation, function and
persistence of adoptively transferred CTLs (9,10,22). Here,
we have overcome these two barriers by developing a
methodology for the rapid generation of EBV-CTLs, which
are resistant to immunosuppression with calcineurin
inhibitors.
For the rapid generation of virus-specific CTLs, several
groups have utilized IFN-g capture to select antigen-
specific T cells (14,15,23,24). Recently, two groups (16,17)
have reported the clinical application of EBV-CTLs gener-
ated from donor blood using IFN-g capture in the HSCT
setting. In our work, we have used the same peptide pool
described by Moosmann et al (16) that contains 23
immunodominant peptides from a range of EBV latent
and lytic antigens.
In order to generate EBV-CTLs resistant to calcineurin
inhibitors, we have developed a methodology involving
restimulation of CTLs isolated by IFN-g capture with EBV-
peptide loaded autologous feeders followed by retroviral
transduction with CNb30. This approach avoids the use
of live virus and shortens the time taken to generate CTLs
to 14 days, thereby reducing regulatory complexity
and facilitating clinical application. Further, this culture
process has the additional advantage of reducing the
potential for alloreactivity, which has been seen with CTLs
isolated directly after g-capture from HLA-mismatched
donors (25).
EBV-CTLs generated using this approach showed a
similar phenotype to those generated by conventional
LCL stimulation with a predominance of CD8þ T cells with
an effector memory phenotype but also a significant
proportion of helper CD4þ T cells, which are important
for the maintenance of durable antigen-specific responses
after adoptive transfer (26). Using HLA-peptide tetramers,
we have demonstrated significant enhancement of antigen
specificity of EBV-CTLs compared with unmanipulated
PBMCs from the same donor. We need to assess
alloreactivity against graft donor in further studies.
Clearly in the SOT setting, donor blood is often not available
and is generally HLA-mismatched, so that donor derived
CTLs can be rejected and may not recognize tumor B cells,
which are almost always of recipient origin. Rejection of
adoptively transferred CTLs may limit their persistence and
efficacy particularly when partially HLA-mismatched third-
party EBV-CTLs are used (21). Thus, it is critical to evaluate
the feasibility of generating autologous CTLs from SOT
patients receiving immunosuppression. Similar to previous
studies using conventional LCLs (5,8,13), we have shown
that it is possible to generate EBV-CTLs from SOT patients
on immunosuppression using our methodology. Moreover,
we show that the function and antigen specificity is similar
to those generated in healthy donors and we found that the
effect of the immunosuppressive drugs has no effect on
the ex vivo EBV-CTLs as they do not show anergy by
keeping their ability to respond in vitro to viral antigens.
To enable CTLs to function in the presence of immunosup-
pression, our group has previously engineered CTLs to be
resistant to CsA and TAC. Binding of these drugs with their
chaperone proteins to the calcineurin heterodimer sterically
blocks entry and subsequent activation of NFAT. We have
designed calcineurinmutations that inhibit docking of either
or both TAC/FKBP12 and CsA/CyPA complexes, but do not
affect the active site. The mutant used in our current
experiments, CNb30, has two mutations (L124T point
mutation and insertion K125-LA) that disrupt binding of
FKBP12/CyPA to the calcineurin heterodimer but do
not affect NFAT dephosphorylation. Consistent with our
previous study (11), here we show that EBV-CTLs
generated using our novel methodology, when transduced
with CNb30, are able to proliferate and secrete the Th1
effector cytokine IFN-g in response to stimulation with EBV
peptides even in the presence of TAC, whereas EBV-CTLs
transduced with a control vector were not. Cytotoxicity
is unaffected by calcineurin inhibitors, and both CNb30-
CTLs and CTLs transduced with a control vector were able
to lyse autologous EBV-infected targets effectively in the
presence of TAC. Importantly, CNb30-CTLs were devoid of
in vitro alloreactivity, suggesting they are unlikely to cause
graft rejection. Likewise, since transduced EBV-CTLs
are terminally differentiated, retroviral gene transfer is
extremely unlikely to result in leukemogenesis: indeed
there are no reported cases of this in over 200 patients
treated with retrovirally transduced T cells.
The methodology described here will greatly facilitate
translation of this approach to clinical use in the SOT setting
by enabling generation of autologous EBV-CTLs resistant to
immunosuppression without the need for replication-
competent EBV in a timely fashion. Our approach is animal
serum-free; the EBV pepmix is recombinant and has been
used in two previous clinical studies, and the IFN-g capture
approach has been used clinically by a number of groups
to generate virus-specific CTLs for adoptive trans-
fer (16,17,24). We are currently scaling up our approach
for clinical use under good manufacturing practice
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conditions. As shown by our data in SOT recipients, one
challenge will be to generate an adequate cell dose of
CNb30-EBV-CTLs from patients on immunosuppression.
Previous studies with EBV-CTLs in the HSCT setting have
shown efficacy at a cell dose of 2107/m2. While we are
routinely able to generate such doses from a 500mL blood
draw from normal donors, this may not be feasible in SOT
patients, particularly children. We are currently investigat-
ing alternate cytokine regimens and culture in gas-perme-
able bioreactors (27) to optimize CTL expansion.
In summary, we have developed a simple, robust and
potentially clinically applicable methodology for the rapid
generation of EBV-CTLs resistant to immunosuppression.
Potentially, adoptive transfer of autologous calcineurin
inhibitor resistant EBV-CTLs could be used as prophylaxis
for PTLD in high-risk groups, such as in patients undergoing
pediatric small bowel transplantation, where the risk of PTLD
may be as high as 30% (28). In cohorts at lower risk of
PTLD, resistant EBV-CTLs could be used as adjunctive
therapy for establishedPTLDwithRituximab. In this situation,
first-line therapy with Rituximab could be used to establish
disease control during the time required for generation of the
EBV-CTLs, with subsequent transfer of resistant CTLs to
maintain remission and overcome the significant rates of
partial response and relapse associated with Rituximab
monotherapy (29) without the toxicity associated with
chemotherapy (30). Critically, such a strategy would obviate
the need for reduction in immunosuppression with calci-
neurin inhibitors, which is a frequent cause of rejection and
treatment failure (31). Such an approach could be of major
benefit to PTLD patients by reducing the morbidity and
mortality without the need for withdrawal of immunosup-
pression with calcineurin inhibitors.
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